Clinical trials: Plaque Psoriasis Subjects
Psoriasis Vulgaris
A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis
This is a randomized, double-blind, placebo-controlled, multicentered phase III clinical study to evaluate the efficacy and safety of AK101 in the treatment of subjects with moderate-to-severe plaque psoriasis.
- Trial name
- NCT05120297
- Testing
- AK101
- Where
- 52 sites in China
- Volunteers
- 452 people
- Sponsor
- Akeso
Psoriasis
Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
This study is to evaluate the efficacy and safety for long term use of M518101 in subjects with plaque psoriasis.
- Trial name
- NCT01908595
- Testing
- M518101
- Where
- 31 sites in United States
- Volunteers
- 480 people
- Sponsor
- Maruho North America Inc.
Plaque Psoriasis
A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy
The primary objective of the study is to assess the efficacy and safety of the combination of apremilast plus topical therapies for the treatment of adults with plaque psoriasis who have not achieved an adequate response with…
- Trial name
- NCT03930186
- Testing
- Apremilast, Topical Therapy
- Where
- 56 sites in Germany, Japan
- Volunteers
- 152 people
- Sponsor
- Amgen
Moderate-to-severe Chronic Plaque Psoriasis
Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis
This is a multi-regional, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SHR-1314 in adults with moderate-to-severe plaque psoriasis.
- Trial name
- NCT03463187
- Testing
- SHR-1314
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 211 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Psoriasis
Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
The study is a randomized, double blinded, vehicle and active comparator controlled, multiple dose study in subjects with chronic plaque psoriasis. The study will have approximately 15 completers.
- Trial name
- NCT03469336
- Testing
- PF-06763809, Vehicle, Calcipotriene/calcipotriol
- Where
- 2 sites in Germany
- Volunteers
- 18 people
- Sponsor
- Pfizer
Plaque Psoriasis
Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled multicenter clinical trial targeting subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT07130604
- Testing
- D-2570
- Where
- China
- Volunteers
- 390 people
- Sponsor
- InventisBio Co., Ltd
Psoriasis
The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis
The purpose of this study is to determine the safety and effectiveness in the treatment of psoriasis on the scalp and on the body.
- Trial name
- NCT01139580
- Testing
- Calcipotriene Foam, Vehicle Foam
- Where
- 26 sites in United States
- Volunteers
- 363 people
- Sponsor
- Stiefel, a GSK Company
Plaque Psoriasis
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
This is a parallel group, double blind, vehicle-controlled study in which roflumilast (ARQ-151) cream 0.3%, roflumilast cream 0.15%, or vehicle cream is applied once daily (QD) for 84 days to subjects with chronic plaque…
- Trial name
- ARQ-151-201 (NCT03638258)
- Testing
- Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream
- Where
- 30 sites in United States, Canada
- Volunteers
- 331 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Psoriasis
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT03701763
- Testing
- Apremilast (CC-10004)
- Where
- 99 sites in United States, Belgium and 8 more
- Volunteers
- 245 people
- Sponsor
- Amgen
Psoriasis
A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of Ustekinumab in the treatment of patients with moderate to severe psoriasis in South Korea and Taiwan.
- Trial name
- NCT00747344
- Testing
- Ustekinumab 45 mg - CP, Ustekinumab 45 mg - after CP
- Where
- 5 sites in South Korea, Taiwan
- Volunteers
- 121 people
- Sponsor
- Centocor, Inc.
Plaque Psoriasis Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis.
Phase III Efficacy and Safety Study of RSS0393 Ointment in Plaque Psoriasis.
- Trial name
- NCT07543224
- Testing
- RSS0393 ointment 0.03%
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Reistone Biopharma Company Limited
Psoriasis
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to…
- Trial name
- NCT01815424
- Testing
- CP-690,550
- Where
- 24 sites in China, South Korea and 1 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Plaque Psoriasis
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
The aim of this study is to investigate the utility of a technological based rating scale for assessing improvement in plaque psoriasis with Clobex spray treatment.
- Trial name
- NCT01893567
- Testing
- Clobex Spray
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Galderma R&D
Moderate-to-severe Chronic Plaque Psoriasis
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
The study has been designed with three components. Part A is an open label PK study followed by a randomized trial component (Part B) followed by open label Long Term Extension (LTE).
- Trial name
- NCT03997786
- Testing
- Tildrakizumab, Etanercept
- Where
- 27 sites in United States, Hungary and 4 more
- Volunteers
- 135 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Chronic Plaque Psoriasis
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
Comparison of two dosing regimens of Alefacept in subjects weighing between 100kg and 150kg with moderate to severe Chronic Plaque Psoriasis
- Trial name
- NCT00674063
- Testing
- alefacept
- Where
- 17 sites in United States, Canada
- Volunteers
- 78 people
- Sponsor
- Astellas Pharma Inc
Psoriasis
Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet
Evaluate the efficacy and safety of a 16-week course of Humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.
- Trial name
- NCT00735787
- Testing
- Adalimumab
- Where
- 17 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- Abbott
Psoriasis
A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to assess the safety and tolerability of CNTO 1959 following a single subcutaneous (SC, under the skin) dose administered to Japanese participants with moderate to severe plaque psoriasis.
- Trial name
- NCT01484587
- Testing
- CNTO 1959
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Janssen Pharmaceutical K.K.
Psoriasis
A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis
The purpose of this study is to determine whether DRM02 is safe and effective in the treatment of plaque psoriasis when applied twice daily for 6 weeks.
- Trial name
- NCT01993433
- Testing
- DRM02, Vehicle
- Where
- 2 sites in Canada
- Volunteers
- 23 people
- Sponsor
- Dermira, Inc.
Plaque Psoriasis
Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis
Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.
- Trial name
- NCT00437255
- Testing
- Clobetasol Propionate, 0.05%, Calcipotriene and betamethasone dipropionate ointment
- Where
- 4 sites in United States
- Volunteers
- 122 people
- Sponsor
- Galderma R&D
Psoriasis
The Effect of Algae Dunaliella Bardawil on Psoriasis (2)
This is a Randomized, Double-Blind, , Placebo Controlled, 18 Week Study To Evaluate the Efficacy of adjuvant 9-cis-β-Carotene Rich powder of the Alga Dunaliella bardawil in Subjects With Plaque type Psoriasis treated by Narrow…
- Trial name
- NCT01121081
- Testing
- Alga Dunaliella Bardawil
- Where
- Israel
- Sponsor
- Sheba Medical Center